Mydriasis as a Side Effect of Dinutuximab Immunotherapy in Pediatric Neuroblastoma: A Case Series

Dinutuximab is a monoclonal antibody against disialoganglioside GD2, a glycosphingolipid strongly expressed on neuroblastoma cells and minimally expressed on normal peripheral nerve cells. While dinutuximab improves survival in high-risk pediatric neuroblastoma, it has also been reported to cause side effects of peripheral neuropathy that typically involve the limbs. We report three cases of children with neuroblastoma who developed mydriasis following treatment with dinutuximab.